EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Rhabdoid Tumor of the Kidney and Soft Tissues: Results from National Wilms Tumor Study‐5 and Children's Oncology Group Study AREN0321

James I Geller iD, Lindsay A Renfro, Paul E Grundy, Elizabeth J Perlman, John A Kalapurakal, Peter F Ehrlich iD, Jackie Biegel, Vicki Huff, Anne B Warwick, Arnold Paulino iD, Elizabeth A Mullen, Najat C Daw und 8 weitere

Pediatric Blood & Cancer · 2025

DOI: 10.1002/pbc.31490 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von James I Geller und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Oncology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio, USA. Hauptthemen laut MEDLINE: Rhabdoid Tumor, Kidney Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Soft Tissue Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: St. Baldrick's Foundation, NCI NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

National Wilms Tumor Study‐5 (NWTS‐5) and AREN0321 evaluated the outcomes of children with rhabdoid tumor of the kidney (RTK) and malignant rhabdoid tumor of soft tissues (MRT). Patients and Methods Eligible patients with RTK were enrolled prospectively on NWTS‐5 (1995–2002) and treated with carboplatin and etoposide alternating with cyclophosphamide (Regimen RTK). Patients with RTK or MRT were enrolled on AREN0321 (2005–2012) and received vincristine, doxorubicin, and cyclophosphamide alternating with carboplatin, cyclophosphamide, and etoposide (Regimens UH‐1 or dose‐reduced Revised UH‐1). We report event‐free survival (EFS) and overall survival (OS) from each study.

Results

Thirty patients received Regimen RTK on NWTS‐5; on AREN0321, 20 received UH‐1 and 19 received Revised UH‐1. Patient and disease characteristics were statistically similar between studies. Patients on AREN0321 had significantly improved EFS and OS compared to those on NWTS‐5 (4‐year EFS = 23.1% vs. 16.7%; p = 0.020; 4‐year OS = 30.6% vs. 20.0%; p = 0.014), mostly driven by patients with Stage I/II disease ( p = 0.05). Median time to an event was 3.6 months on NWTS‐5 compared to 7.2 months on AREN0321. There were no differences in EFS or OS by revised versus original Regimen UH‐1 on AREN0321, or by renal versus extra‐renal primary disease when the studies were pooled.

Conclusions

The more intensive treatment regimen used on AREN0321 improved EFS and OS overall, a result driven by patients with Stage I/II disease. Despite this improvement, outcomes for patients with rhabdoid tumor remain unsatisfactory and there is a need for novel therapeutic strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rhabdoid TumorKidney NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsSoft Tissue NeoplasmsHumansFemaleMaleChild, PreschoolInfantChildEtoposideSurvival RateCyclophosphamideVincristineProspective StudiesCarboplatinDoxorubicinFollow-Up StudiesAdolescentPrognosisWilms Tumor

Stichwörter der Autor:innen

chemotherapypediatric oncologyrenalrhabdoid tumortumors

Substanzen

EtoposideCyclophosphamideVincristineCarboplatinDoxorubicin

Autor:innen und Institutionen

  • Division of Pediatric Oncology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio, USA.
  • Division of Biostatistics, University of Southern California and Children's Oncology Group, Los Angeles, California, USA.
  • Division of Immunology, Hematology, Oncology, Palliative Care, and Environmental Interactions, University of Alberta, Edmonton, Alberta, Canada.
  • Department of Pathology and Laboratory Medicine, Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • Department of Radiation Oncology, Northwestern University, Chicago, Illinois, USA.
  • Section of Pediatric Surgery, CS Mott Children's Hospital, University of Michigan, Ann Arbor, Michigan, USA.

ORCID-Profile: James I Geller, Peter F Ehrlich, Arnold Paulino

Förderung

  • St. Baldrick's Foundation
  • NCI NIH HHS
  • NIH HHS
  • US Public Health Service
  • National Cancer Institute
  • National Institutes of Health

Zitieren

APA

Geller, J. I., Renfro, L. A., Grundy, P. E., Perlman, E. J., Kalapurakal, J. A., Ehrlich, P. F., Biegel, J., Huff, V., Warwick, A. B., Paulino, A., Mullen, E. A., Daw, N. C., Hoffer, F. A., Tochner, Z., Gow, K., Gratias, E., Ward, D. A., Anderson, J. R., Fernandez, C. V., & Dome, J. S. (2025). Rhabdoid Tumor of the Kidney and Soft Tissues: Results from National Wilms Tumor Study‐5 and Children's Oncology Group Study AREN0321. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31490

Vancouver

Geller JI, Renfro LA, Grundy PE, Perlman EJ, Kalapurakal JA, Ehrlich PF, et al. Rhabdoid Tumor of the Kidney and Soft Tissues: Results from National Wilms Tumor Study‐5 and Children's Oncology Group Study AREN0321. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31490

BibTeX
@article{Geller2025,
  author = {Geller, James I and Renfro, Lindsay A and Grundy, Paul E and Perlman, Elizabeth J and Kalapurakal, John A and Ehrlich, Peter F and Biegel, Jackie and Huff, Vicki and Warwick, Anne B and Paulino, Arnold and Mullen, Elizabeth A and Daw, Najat C and Hoffer, Fredric A and Tochner, Zelig and Gow, Kenneth and Gratias, Eric and Ward, Deborah A and Anderson, James R and Fernandez, Conrad V and Dome, Jeffrey S},
  title = {Rhabdoid Tumor of the Kidney and Soft Tissues: Results from National Wilms Tumor Study‐5 and Children's Oncology Group Study AREN0321},
  journal = {Pediatric Blood & Cancer},
  year = {2025},
  doi = {10.1002/pbc.31490}
}
Kostenlos starten →